Sachdev Thomas is an Oncology physician. OpenAlex indexes 212 publications with 1,871 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8940 N Wood Sage Rd
Peoria, IL 616157822
Telephone
309-243-3000Registry record last updated 17 Dec 2021.
Clinical trials
- GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Sponsor: Illinois CancerCare, P.C.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year202511 payments$11,544openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
54.4%Cytochrome P450 17A1 Inhibitor23%Abiraterone Acetate100%Part D≥60 patientsThalidomide Analog11.3%Lenalidomide87%Pomalyst7%Revlimid6%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
21.3%Corticosteroid15%Prednisone100%Part D≥78 patientsPotassium supplement2.6%Potassium Chloride100%Part D≥17 patients+ 2 more classes in this area
Nervous system
9.7%Phenothiazine6.9%Prochlorperazine Maleate81%Compro19%Part D≥47 patientsOpioid Agonist1.5%Oxycodone Hcl100%Part D≥12 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evaluation of a predictive biomarker for antibody drug conjugates (ADCs).
Journal of Clinical Oncology
2024 - Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Communications Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”